Literature DB >> 1571465

Invasive aspergillosis in patients with AIDS.

G Y Minamoto1, T F Barlam, N J Vander Els.   

Abstract

Invasive aspergillosis is a rare complication of AIDS. We discuss the cases of 18 patients with AIDS and invasive aspergillosis who were identified at our institution and 19 patients who are described in the literature. Twenty-one patients were either homosexual or bisexual, eight were intravenous drug users, three were hemophiliacs, two attributed their disease to a heterosexual contact, and one was a transfusion recipient; risk factors for AIDS were unknown for two patients. Twenty-eight of the 37 patients had pulmonary aspergillosis; for 18 of these 28, the lung was the sole site of disease. Aspergillosis involved the brain in 12 cases, the heart in five cases, and the kidney, sinuses, or skin in six other cases. Eleven patients had multiple sites of disease, and eight patients had extrapulmonary disease alone. Possible risk factors for aspergillosis included leukopenia (7 patients, of whom 5 were also neutropenic) and use of corticosteroids (8 patients), alcohol (6 patients), broad-spectrum antibiotics (5 patients), and antineoplastic agents (4 patients); 14 patients had no identifiable risk. Death was the usual outcome, despite treatment of patients with amphotericin B. In cases of AIDS and invasive aspergillosis, early diagnosis may lead to improved outcome.

Entities:  

Mesh:

Year:  1992        PMID: 1571465     DOI: 10.1093/clinids/14.1.66

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  23 in total

Review 1.  In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection.

Authors:  William J Steinbach; John R Perfect; Wiley A Schell; Thomas J Walsh; Daniel K Benjamin
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

2.  The Aspergillus fumigatus siderophore biosynthetic gene sidA, encoding L-ornithine N5-oxygenase, is required for virulence.

Authors:  Anna H T Hissen; Adrian N C Wan; Mark L Warwas; Linda J Pinto; Margo M Moore
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Fungicidal activity of cecropin A.

Authors:  A J DeLucca; J M Bland; T J Jacks; C Grimm; T E Cleveland; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

4.  Proton-pumping-ATPase-targeted antifungal activity of a novel conjugated styryl ketone.

Authors:  E K Manavathu; J R Dimmock; S C Vashishtha; P H Chandrasekar
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

5.  Serum stimulates growth of and proteinase secretion by Aspergillus fumigatus.

Authors:  Anna H T Gifford; Jodine R Klippenstein; Margo M Moore
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

6.  Binding of human fibronectin to Aspergillus fumigatus conidia.

Authors:  M C Peñalver; J E O'Connor; J P Martinez; M L Gil
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

7.  Management of pulmonary aspergillosis in AIDS: an emerging clinical problem.

Authors:  J J Keating; T Rogers; M Petrou; J D Cartledge; D Woodrow; M Nelson; D A Hawkins; B G Gazzard
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

8.  Virulence studies of Aspergillus nidulans mutants requiring lysine or p-aminobenzoic acid in invasive pulmonary aspergillosis.

Authors:  C M Tang; J M Smith; H N Arst; D W Holden
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

9.  Survival of Aspergillus fumigatus in serum involves removal of iron from transferrin: the role of siderophores.

Authors:  A H T Hissen; J M T Chow; L J Pinto; M M Moore
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

10.  Spinal epidural aspergillosis in a patient with HIV resulting from long-standing (3 years) lung infection.

Authors:  R D Murtagh; M J D Post; J Bruce; K K Post
Journal:  AJNR Am J Neuroradiol       Date:  2007-10-09       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.